LAX.SH
PIRAMAL PHARMA LIMITED·PHARMACEUTICALS 66.37CDMO 77.10·Pharmaceuticals & Biotechnology Companies
Price
194.99
+1.98%52W Range
Market Cap
₹25,959.96 Cr
Traded: ₹54.83 Cr (0.21%) 0.0x
Free Float: ₹4,597.51 Cr (1.19% of FF traded)
Volume · 60D trend
28.36 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +0.0% | -1.0% | -- | -- | Decelerating |
| Return | -- | -- | +32.0% | -24.0% | -- | Decelerating |
| Sales | -- | +7.0% | +8.0% | -- | -3.0% | Stable |
| Profit | -- | -- | -24.0% | -- | -429.0% | Decelerating |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,270 | 2,752 | 2,140 | 2,044 | 1,934 | 2,754 | 2,204 | 2,242 | 1,951 | 2,552 | 1,959 | 1,911 | 1,749 | 2,164 | 1,716 |
| Expenses | 2,075 | 2,291 | 1,944 | 1,885 | 1,827 | 2,193 | 1,866 | 1,900 | 1,747 | 2,022 | 1,690 | 1,646 | 1,617 | 1,812 | 1,629 |
| Operating Profit | 195 | 461 | 196 | 159 | 107 | 561 | 338 | 342 | 204 | 530 | 268 | 266 | 132 | 351 | 87 |
| Other Income | 109 | -116 | 12 | 80 | 98 | 58 | 29 | 78 | 42 | 8 | 43 | 68 | 53 | 32 | 98 |
| Interest | 88 | 83 | 89 | 82 | 86 | 104 | 103 | 108 | 107 | 114 | 106 | 110 | 119 | 104 | 95 |
| Depreciation | 224 | 218 | 213 | 203 | 197 | 243 | 197 | 192 | 185 | 196 | 186 | 185 | 174 | 184 | 164 |
| Profit Before Tax | -7 | 43 | -94 | -46 | -79 | 273 | 67 | 120 | -45 | 227 | 19 | 40 | -107 | 95 | -74 |
| Tax % | 830.0% | 121.0% | 45.0% | 115.0% | 3.0% | 44.0% | 94.0% | 81.0% | 97.0% | 55.0% | 48.0% | 87.0% | -8.0% | 47.2% | 22.0% |
| Net Profit | -69 | -9 | -136 | -99 | -82 | 154 | 4 | 23 | -89 | 101 | 10 | 5 | -99 | 50 | -90 |
| Exceptional Items | -- | -176 | -41 | 0 | 21 | 0 | 0 | 0 | 0 | -31 | -32 | 0 | 0 | 0 | 0 |
| EPS (Rs) | -0.5 | -0.1 | -1.0 | -0.8 | -0.6 | 1.2 | 0.0 | 0.2 | -0.7 | 0.8 | 0.1 | 0.0 | -0.8 | 0.4 | -0.7 |
| Sales Growth (YoY) | 17.4% | -0.1% | -2.9% | -8.8% | -0.9% | 7.9% | 12.5% | 17.3% | 11.6% | 18.0% | 14.1% | 11.1% | 18.0% | -- | -- |
| Sales Growth (QoQ) | -- | 28.6% | 4.7% | 5.7% | -29.8% | 24.9% | -1.7% | 14.9% | -23.6% | 30.3% | 2.5% | 9.3% | -19.2% | 26.1% | -- |
| OP Growth (YoY) | 82.2% | -17.8% | -42.0% | -53.5% | -47.5% | 5.8% | 26.1% | 28.6% | 54.5% | 50.9% | 208.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | -57.7% | 135.2% | 23.3% | 48.6% | -80.9% | 66.0% | -1.2% | 67.6% | -61.5% | 97.8% | 0.8% | 101.5% | -62.4% | 303.8% | -- |
| Profit Growth (YoY) | 26.0% | -25.0% | -3241.0% | -539.0% | -5.0% | 34.0% | -59.0% | 350.0% | 10.0% | 129.0% | 110.0% | 113.0% | 10.0% | -75.0% | -155.0% |
| EPS Growth (YoY) | -- | -106.0% | -3500.0% | -541.2% | 9.0% | 50.6% | -62.5% | 325.0% | 10.7% | 102.6% | 111.8% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 93.1% | -36.0% | -22.9% | -152.6% | 3766.7% | -82.3% | 125.4% | -187.0% | 862.5% | 100.0% | 105.3% | -297.4% | 155.9% | -- |
| OP Margin | -- | 16.7% | 9.2% | 7.8% | 5.5% | 20.4% | 15.3% | 15.2% | 10.5% | 20.8% | 13.7% | 13.9% | 7.6% | 16.2% | 5.1% |
| Net Margin | -- | -0.3% | -6.4% | -4.8% | -4.2% | 5.6% | 0.2% | 1.0% | -4.5% | 4.0% | 0.5% | 0.3% | -5.6% | 2.3% | -5.2% |
| Material Cost % | -- | 38.4% | 36.8% | 34.4% | 35.9% | 34.7% | 36.6% | 35.5% | 34.6% | 39.7% | 34.5% | 33.4% | 35.8% | 38.8% | 36.4% |
| Employee Cost % | -- | 21.3% | 28.0% | 29.9% | 32.0% | 22.2% | 25.2% | 25.0% | 29.7% | 19.4% | 26.7% | 27.0% | 28.3% | 21.9% | 28.7% |
| P/S | 2.82 | 2.94 | 2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.18 | 3.19 | 2.71 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find enclosed intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ('SEBI Listing Regulations')
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Please refer attachment.
Please refer attachment.
The Exchange has sought Clarification from Piramal Pharma Ltd with reference to the media report appearing on https://www.thehindubusinessline.com/ dated September 30, 2026 (Link: https://www.thehindubusinessline.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526588.ece) ....
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Changes in Senior Management Personnel.
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Appointment of Senior Management Personnel.
Please refer the attachment.
Please refer attachment.
Please refer attached file
Please refer attached file
Please refer attached file
Please refer attached file
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
Please refer attached file
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
Please find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited
Please find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Report of the Scrutinizer along with the voting results of the businesses transacted at the AGM
Proceedings and Voting Results of the 6th Annual General Meeting of the Company
Please find enlcosed UFR Q1 FY 27.
Please refer attachment.
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
Successful closure of US FDA Inspection at Piramal Pharma''s manufacturing facility located at Sellersville (USA) facility
Newspaper Advertisement for dispatch of notice of the 6th Annual General Meeting and E-Voting information
Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025-26
Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025-26
Business Responsibility and Sustainability Reporting for the Financial Year 2025-26
Please refer attached file
The Exchange has sought clarification from Piramal Pharma Ltd on June 23, 2026, with reference to news appeared in https://www.ndtvprofit.com dated June 23, 2026, quoting "Piramal Pharma ....
Please refer attached file
Newspaper Advertisement for information regarding 6th Annual General Meeting of the Company
Please find enclosed intimation of allotment of ESOPs.
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Please find enclosed herewith the Annual Secretarial Compliance Report for the Financial Year 2025-2026.
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Please refer attached file
Please refer attached file
Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026
Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026
Please refer attached file
Please find enclosed outcome of the Board Meeting held on April 28, 2026
Please refer attached details of change in management.
Please refer attached.
Please refer attached details of change in directorate.
Please refer attached.
Please refer attached details of cessation of Interim Company Secretary and Compliance Officer
Credit Ratings
6Concalls
24Jan 2026
31 Jan 2026Nov 2025
30 Nov 2025Oct 2025
31 Oct 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Oct 2024
31 Oct 2024Sep 2024
30 Sept 2024Jul 2024
31 Jul 2024Jul 2024
31 Jul 2024May 2024
31 May 2024May 2024
31 May 2024Jan 2024
31 Jan 2024Jan 2024
31 Jan 2024Oct 2023
31 Oct 2023Oct 2023
31 Oct 2023Aug 2023
31 Aug 2023May 2023
31 May 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Jan 2023
31 Jan 2023Nov 2022
30 Nov 2022Held by ETFs
21 ETFs hold PPLPHARMA · sorted by weight
Held by Mutual Funds
48 schemes hold PPLPHARMA · sorted by weight